Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03026803 · ClinicalTrials.gov registry record · Phase 2
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
A Phase 2 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03026803 is a Phase 2 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT03026803, a Phase 2 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving oxaliplatin and capecitabine together works in treating patients with liver cancer.
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-11 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03026803
The ClinicalTrials.gov registry entry for NCT03026803 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT03026803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03026803 about?
NCT03026803 is a clinical study titled "A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer". This phase II trial is studying how well giving oxaliplatin and capecitabine together works in treating patients with liver cancer.
What is the current status of trial NCT03026803?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2006-11. Estimated completion is 2014-10.
What interventions are being tested in trial NCT03026803?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT03026803?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.